Stifel lowered the firm’s price target on Apellis (APLS) to $48 from $55 and keeps a Buy rating on the shares as part of a 2026 outlook note for the analyst’s Biopharma coverage.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis Pharmaceuticals: Buy Rating Affirmed Amidst European Regulatory Milestones and Long-term Growth Potential
- Roth Capital healthcare analyst holds an analyst/industry conference call
- Buy Rating for Apellis Pharmaceuticals: Strong Empaveli Launch and Long-term Syfovre Potential
- Apellis announces NEJM published ‘positive’ Phase 3 EMPAVELI study data
- Apellis announces 5-year GALE data showing SYFOVRE delayed progression of GA